|
Prior to COVID-19 (n=54) |
During COVID-19 (n=177) |
p-value |
Drug-related issues |
|
|
|
Adverse drug reaction |
0 |
1 (0.6%) |
1.000 |
Drug monitoring |
2 (3.7%) |
2 (1.1%) |
0.234 |
Drug without indication |
18 (33.3%) |
30 (16.9%) |
0.013 |
Failure to receive a drug |
0 |
1 (0.6%) |
1.000 |
Improper administration |
5 (9.3%) |
42 (23.7%) |
0.021 |
Non conformity to guidelines or contraindication |
13 (24.1%) |
41
(23.2%) |
0.857 |
Subtherapeutic dosage |
5 (9.3%) |
3 (1.7%) |
0.019 |
Supratherapeutic dosage |
11 (20.4%) |
51 (28.8%) |
0.292 |
Untreated indication |
0 |
6 (3.4%) |
0.340 |
Therapeutic advice |
|
|
|
Addition of a new drug |
2 (3.7%) |
16 (9.0%) |
0.257 |
Administration modalities optimisation |
1 (1.9%) |
27 (15.3%) |
0.007 |
Change of administration route |
2 (3.7%) |
8 (4.5%) |
1.000 |
Dose adjustment |
13 (24.1%) |
44 (24.9%) |
1.000 |
Drug discontinuation |
26 (48.1%) |
46 (26.0%) |
0.004 |
Drug monitoring |
2 (3.7%) |
3 (1.7%) |
0.333 |
Drug switch |
8 (14.8%) |
33 (18.6%) |
0.684 |